Navigation Links
NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
Date:10/15/2009

NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA-approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009

FORT WASHINGTON, Pa., Oct. 15 /PRNewswire-USNewswire/ -- Upon the recent FDA approval of pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), the National Comprehensive Cancer Network (NCCN) has updated the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include pralatrexate as a suggested treatment regimen.

The updated NCCN Guidelines have added pralatrexate as a second-line therapy option for relapsed or refractory PTCL with a category 2A recommendation for patients who are not candidates for high dose therapy and a category 2B recommendation for patients who are candidates for high dose therapy.

Peripheral T-cell lymphoma is a rare form of non-Hodgkin's lymphoma that is particularly aggressive and challenging to treat. Pralatrexate recently became the first FDA-approved single agent therapy indicated for patients with relapsed or refractory disease, meaning those whose disease has returned or has not responded to other types of therapy.

NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org.

About the National Comprehensive Cancer Network

The Nationa
'/>"/>

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. BioCryst Updates Peramivir Clinical Development Plan
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Also ... is an increasingly popular weight loss surgery that guarantees ... Lap Band Center wishes to give readers a ... Dr. Naim attended medical school at New York City’s ... New York Methodist he undertook a fellowship in Minimally ...
(Date:5/18/2013)... 18, 2013 Online watch retailer Time and ... watch owners at a fraction of its usual cost. ... in the world, buyers are urged to take advantage of ... a Rolex watch from a brick-and-mortar store, buyers now have ... watches priced at unbelievable rates. Although some buyers may have ...
(Date:5/18/2013)... (PRWEB) May 19, 2013 Illuminations is proud ... Trisha Caetano. Seminars will take place over the course ... Friday, June 7, and Saturday, June 8, 2013. , Inner ... symptoms, but focuses on the attitudes, patterns and coping mechanisms ... symptoms. Participants will learn to live a more integrated and ...
(Date:5/18/2013)... Dennis Thompson HealthDay Reporter , , FRIDAY, May ... unveils the latest edition of what is considered the ... its many changes continues. "This is unprecedented, the ... Jeffrey Lieberman, president-elect of the American Psychiatric Association (APA). ... what it is. You have to evaluate it and ...
(Date:5/18/2013)... 18 (HealthDay News) -- Children who swallow high-powered magnets ... the objects, according to a new study. The ... New Orleans, found that more than 79 percent of ... surgery or an endoscopic procedure, in which a tube ... Only 21 percent of these cases can be treated ...
Breaking Medicine News(10 mins):Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Swallowing Magnets Can Be Fatal for Children 2
... UCSF research team has developed a technique to ... differences in levels of genetic markers. Standard ... and somewhat subjective, the researchers say, and supplementing ... to help clarify difficult-to-diagnose cases. , In a ...
... Today; Donate Life Hollywood Film Fest June 13 ... Pounds is released on DVD today and while critics ... organ and tissue donation/transplant community can be critical of Hollywood,s ... wrong, which costs lives," says Donate Life Hollywood Campaign Director, ...
... were missed, could be more prominent , , MONDAY, March 30 ... of over-the-counter pain relievers recently, she was surprised to find ... it. , Bix, the mother of three small children and ... State University, knew that one size of any product line ...
... Largest Study on a Test that Identifies Tumors with ... Pathwork Diagnostics, Inc., a molecular diagnostics company focused ... Clinical Oncology (JCO) has published the ... study in a paper entitled, "Multicenter Validation of a ...
... FOREST, Ill., March 30 Hospira, Inc. (NYSE: ... medication delivery company, today announced that it will host ... on Tuesday, April 28, 2009, at 8 a.m. Central ... results earlier that morning, before the U.S. stock market ...
... Standard therapy wipes out any protection the supplement might ... -- Patients receiving optimal drug therapy after suffering a ... taking supplemental omega-3 fatty acids, a new study finds. ... suffered heart attacks, researchers found no difference in rates ...
Cached Medicine News:Health News:New strategy developed to diagnose melanoma 2Health News:New strategy developed to diagnose melanoma 3Health News:Labels on OTC Painkillers Need Improvement 2Health News:Labels on OTC Painkillers Need Improvement 3Health News:Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology 2Health News:Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology 3Health News:Omega-3s of No Added Benefit to Heart Attack Patients 2Health News:Omega-3s of No Added Benefit to Heart Attack Patients 3
... The ID-Micro Typing System™ (ID-MTS) ... a broad range of blood ... antibody screening and identification, ABO ... compatibility testing, reverse serum grouping ...
... The Mini-PROTEAN 3 Dodeca cell runs ... conditions in just 35 minutes. Handcast gels ... with the new Model 485 gradient former ... of variation and improving reproducibility. Alternatively, Ready ...
... gels run in the specially designed E-Base™ ... power supply in one device. The daughter ... and to other daughter E-Base™ platforms for ... E-Gel® 96 or E-Gel® 48 gels. Note: ...
... E-Page™ High-Throughput (HTP) Protein ... only integrated pre-cast gel ... high-throughput protein analysis. It ... gels, E-Base™ integrated power ...
Medicine Products: